董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Raymond Stevens | 男 | Director, Chief Executive Officer | 59 | 842.99万美元 | 377.33 | 2023-02-06 |
| Daniel G. Welch | 男 | Chairman of the Board | 65 | 未披露 | 未持股 | 2023-02-06 |
| Ramy Farid | 男 | Director | 58 | 未披露 | 未持股 | 2023-02-06 |
| Sharon Tetlow | 女 | Director | 63 | 36.00万美元 | 11.44 | 2023-02-06 |
| Eric Dobmeier | 男 | Director | 54 | 35.25万美元 | 9.88 | 2023-02-06 |
| Joanne Waldstreicher | 女 | Director | 62 | 35.50万美元 | 9.88 | 2023-02-06 |
| Daniel G. Welch | 男 | Chairman of the Board | 65 | 53.15万美元 | 133.70 | 2023-02-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Raymond Stevens | 男 | Director, Chief Executive Officer | 59 | 842.99万美元 | 377.33 | 2023-02-06 |
| Jun Yoon | 男 | Chief Financial Officer | 45 | 446.76万美元 | 未持股 | 2023-02-06 |
| Xichen Lin | 男 | Chief Scientific Officer | 49 | 248.07万美元 | 53.72 | 2023-02-06 |
| Mark Bach | 男 | Chief Medical Officer | 66 | 61.59万美元 | 未持股 | 2023-02-06 |
| Melita Sun Jung | 女 | Chief Business Officer | 46 | 未披露 | 未持股 | 2023-02-06 |
| Yingli Ma | 女 | Chief Technology Officer | 49 | 199.89万美元 | 未持股 | 2023-02-06 |
董事简历
中英对照 | 中文 | 英文- Raymond Stevens
-
Raymond Stevens自2019年5月起担任Structure Therapeutics公司首席执行官，自2019年2月起担任Structure Therapeutics公司董事会成员。此前，Stevens博士在南加州大学创立了Bridge研究所，即Bridge研究所，2014年7月至2019年5月担任创始主任和教授，此后担任名誉教授。在创立Bridge Institute之前，Stevens博士于2012年1月在上海科技大学创立了iHuman Institute，即iHuman Institute，此后他一直担任创始董事和兼职教授。在创立iHuman研究所之前，Stevens博士于1999年6月至2014年7月担任斯克里普斯研究所综合结构和计算生物学和化学系教授。史蒂文斯博士目前还担任丹纳赫公司（纽约证券交易所代码：DHR）的董事会成员。史蒂文斯博士在哈佛大学完成了化学博士后研究。Stevens博士在南缅因大学获得化学学士学位，在南加州大学获得有机化学博士学位。
Raymond Stevens,has served as Structure Therapeutics Inc. Chief Executive Officer since May 2019 and as a member of Structure Therapeutics Inc. board of directors since February 2019. Previously, Dr. Stevens founded the Bridge Institute at the University of Southern California, or Bridge Institute, where he served as Founding Director and Professor from July 2014 to May 2019, and since then as Professor Emeritus. Prior to founding the Bridge Institute, Dr. Stevens founded the iHuman Institute at ShanghaiTech University, or iHuman Institute, in January 2012, where he has since served as Founding Director and Adjunct Professor. Prior to founding the iHuman Institute, Dr. Stevens served as Professor, Department of Integrative Structural and Computational Biology and Chemistry at The Scripps Research Institute from June 1999 to July 2014. Dr. Stevens also currently serves as a member of the board of directors of Danaher Corporation (NYSE: DHR). Dr. Stevens completed a post-doctoral fellowship in Chemistry at Harvard University. Dr. Stevens received his B.A. in Chemistry from the University of Southern Maine, and his Ph.D. in Organic Chemistry from the University of Southern California. - Raymond Stevens自2019年5月起担任Structure Therapeutics公司首席执行官，自2019年2月起担任Structure Therapeutics公司董事会成员。此前，Stevens博士在南加州大学创立了Bridge研究所，即Bridge研究所，2014年7月至2019年5月担任创始主任和教授，此后担任名誉教授。在创立Bridge Institute之前，Stevens博士于2012年1月在上海科技大学创立了iHuman Institute，即iHuman Institute，此后他一直担任创始董事和兼职教授。在创立iHuman研究所之前，Stevens博士于1999年6月至2014年7月担任斯克里普斯研究所综合结构和计算生物学和化学系教授。史蒂文斯博士目前还担任丹纳赫公司（纽约证券交易所代码：DHR）的董事会成员。史蒂文斯博士在哈佛大学完成了化学博士后研究。Stevens博士在南缅因大学获得化学学士学位，在南加州大学获得有机化学博士学位。
- Raymond Stevens,has served as Structure Therapeutics Inc. Chief Executive Officer since May 2019 and as a member of Structure Therapeutics Inc. board of directors since February 2019. Previously, Dr. Stevens founded the Bridge Institute at the University of Southern California, or Bridge Institute, where he served as Founding Director and Professor from July 2014 to May 2019, and since then as Professor Emeritus. Prior to founding the Bridge Institute, Dr. Stevens founded the iHuman Institute at ShanghaiTech University, or iHuman Institute, in January 2012, where he has since served as Founding Director and Adjunct Professor. Prior to founding the iHuman Institute, Dr. Stevens served as Professor, Department of Integrative Structural and Computational Biology and Chemistry at The Scripps Research Institute from June 1999 to July 2014. Dr. Stevens also currently serves as a member of the board of directors of Danaher Corporation (NYSE: DHR). Dr. Stevens completed a post-doctoral fellowship in Chemistry at Harvard University. Dr. Stevens received his B.A. in Chemistry from the University of Southern Maine, and his Ph.D. in Organic Chemistry from the University of Southern California.
- Daniel G. Welch
-
Daniel G. Welch，自2022年1月起担任Structure Therapeutics公司董事会主席。2015年1月至2018年2月，韦尔奇先生担任风险投资公司Sofinnova Ventures的执行合伙人。在Sofinnova任职之前，Welch先生从2003年9月起担任生物技术公司InterMune，Inc.的首席执行官兼总裁，直到2014年9月被Roche Holdings AG（OTCMKTS：RhHBY）收购。韦尔奇先生还于2008年5月至2014年9月担任InterMune主席。在InterMune任职之前，Welch先生曾担任Triangle Pharmaceuticals，Inc.的董事长兼首席执行官。该公司是一家制药公司，于2002年至2003年被Gilead Sciences，Inc.（纳斯达克股票代码：GILD）收购。在任职于三角药业之前，Welch先生于2000年至2002年在Elan公司（TYO：6099）担任生物制药总裁。在加入Elan公司之前，Welch先生于1987年至2000年在赛诺菲-辛特拉博公司（现为赛诺菲公司（Nasdaq：SNY））担任过多个高级管理职务，包括担任全球营销副总裁和美国业务首席运营官。韦尔奇目前在Nuvation Bio Inc.（纽约证券交易所代码：NUVB）、SeaGen公司（纳斯达克股票代码：SGEN）和Ultragenyx Pharmaceutical Inc.（纳斯达克股票代码：RARE）的董事会任职。韦尔奇先生在迈阿密大学获得市场营销学士学位，在北卡罗来纳大学获得工商管理硕士学位。
Daniel G. Welch,has served as Chairman of Structure Therapeutics Inc. board of directors since January 2022. Mr. Welch served as an Executive Partner of Sofinnova Ventures, a venture capital firm from January 2015 to February 2018. Prior to serving at Sofinnova, Mr. Welch served as Chief Executive Officer and President of InterMune, Inc., a biotechnology company, from September 2003 until its acquisition by Roche Holdings AG (OTCMKTS: RHHBY) in September 2014. Mr. Welch also served as Chairman of InterMune from May 2008 to September 2014. Prior to serving at InterMune, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company that was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) from 2002 to 2003. Prior to serving at Triangle Pharmaceuticals, Mr. Welch served as President of Biopharmaceuticals at Elan Corporation (TYO: 6099) from 2000 to 2002. Prior to serving at Elan, Mr. Welch served in various senior management roles at Sanofi-Synthelabo, now Sanofi S.A. (Nasdaq: SNY), from 1987 to 2000, including as Vice President of Worldwide Marketing and Chief Operating Officer of the U.S. business. Mr. Welch currently serves on the boards of directors of Nuvation Bio Inc. (NYSE: NUVB), SeaGen Inc. (Nasdaq: SGEN), and Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE). Mr. Welch received his B.B.A. in Marketing from the University of Miami and his M.B.A. from the University of North Carolina. - Daniel G. Welch，自2022年1月起担任Structure Therapeutics公司董事会主席。2015年1月至2018年2月，韦尔奇先生担任风险投资公司Sofinnova Ventures的执行合伙人。在Sofinnova任职之前，Welch先生从2003年9月起担任生物技术公司InterMune，Inc.的首席执行官兼总裁，直到2014年9月被Roche Holdings AG（OTCMKTS：RhHBY）收购。韦尔奇先生还于2008年5月至2014年9月担任InterMune主席。在InterMune任职之前，Welch先生曾担任Triangle Pharmaceuticals，Inc.的董事长兼首席执行官。该公司是一家制药公司，于2002年至2003年被Gilead Sciences，Inc.（纳斯达克股票代码：GILD）收购。在任职于三角药业之前，Welch先生于2000年至2002年在Elan公司（TYO：6099）担任生物制药总裁。在加入Elan公司之前，Welch先生于1987年至2000年在赛诺菲-辛特拉博公司（现为赛诺菲公司（Nasdaq：SNY））担任过多个高级管理职务，包括担任全球营销副总裁和美国业务首席运营官。韦尔奇目前在Nuvation Bio Inc.（纽约证券交易所代码：NUVB）、SeaGen公司（纳斯达克股票代码：SGEN）和Ultragenyx Pharmaceutical Inc.（纳斯达克股票代码：RARE）的董事会任职。韦尔奇先生在迈阿密大学获得市场营销学士学位，在北卡罗来纳大学获得工商管理硕士学位。
- Daniel G. Welch,has served as Chairman of Structure Therapeutics Inc. board of directors since January 2022. Mr. Welch served as an Executive Partner of Sofinnova Ventures, a venture capital firm from January 2015 to February 2018. Prior to serving at Sofinnova, Mr. Welch served as Chief Executive Officer and President of InterMune, Inc., a biotechnology company, from September 2003 until its acquisition by Roche Holdings AG (OTCMKTS: RHHBY) in September 2014. Mr. Welch also served as Chairman of InterMune from May 2008 to September 2014. Prior to serving at InterMune, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company that was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) from 2002 to 2003. Prior to serving at Triangle Pharmaceuticals, Mr. Welch served as President of Biopharmaceuticals at Elan Corporation (TYO: 6099) from 2000 to 2002. Prior to serving at Elan, Mr. Welch served in various senior management roles at Sanofi-Synthelabo, now Sanofi S.A. (Nasdaq: SNY), from 1987 to 2000, including as Vice President of Worldwide Marketing and Chief Operating Officer of the U.S. business. Mr. Welch currently serves on the boards of directors of Nuvation Bio Inc. (NYSE: NUVB), SeaGen Inc. (Nasdaq: SGEN), and Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE). Mr. Welch received his B.B.A. in Marketing from the University of Miami and his M.B.A. from the University of North Carolina.
- Ramy Farid
-
Ramy Farid，自2019年4月起担任Structure Therapeutics公司董事会成员。Farid博士自2017年1月起在薛定谔公司（Nasdaq：SDGR）担任总裁兼首席执行官，自1987年起担任多个职务，包括2008年1月至2016年12月担任总裁、2005年1月至2007年12月担任高级副总裁、2003年1月至2004年12月担任科学发展和产品管理副总裁。在加入薛定谔之前，Farid博士于1994年7月至2001年12月担任罗格斯大学化学系助理教授。Farid博士目前担任Schr dinger和Ajax Therapeutics，Inc.的董事会成员。Ajax Therapeutics，Inc.是一家私营生物技术公司，应用计算化学和基于结构的技术开发用于血液系统恶性肿瘤的小分子。Farid博士以前是宾夕法尼亚大学生物化学和生物物理系的国家卫生研究所博士后研究员。Farid博士在罗切斯特大学获得化学学士学位，在加州理工学院获得化学博士学位。
Ramy Farid,has served as a member of Structure Therapeutics Inc. board of directors since April 2019. Since January 2017, Dr. Farid has served as the President and Chief Executive Officer at Schrodinger, Inc. (Nasdaq: SDGR), where he has served in various roles since 1987, including President from January 2008 to December 2016, Senior Vice President from January 2005 to December 2007, and Vice President, Scientific Development and Product Management from January 2003 to December 2004. Prior to joining Schrodinger, Dr. Farid was an Assistant Professor in the Chemistry Department at Rutgers University from July 1994 to December 2001. Dr. Farid currently serves as a member of the board of directors of Schrdinger and Ajax Therapeutics, Inc. a private biotechnology company applying computational chemistry and structure-based technologies to develop small molecules for hematologic malignancies. Dr. Farid was previously a National Institute of Health Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. Dr. Farid received his B.S. in Chemistry from the University of Rochester and his Ph.D. in Chemistry from the California Institute of Technology. - Ramy Farid，自2019年4月起担任Structure Therapeutics公司董事会成员。Farid博士自2017年1月起在薛定谔公司（Nasdaq：SDGR）担任总裁兼首席执行官，自1987年起担任多个职务，包括2008年1月至2016年12月担任总裁、2005年1月至2007年12月担任高级副总裁、2003年1月至2004年12月担任科学发展和产品管理副总裁。在加入薛定谔之前，Farid博士于1994年7月至2001年12月担任罗格斯大学化学系助理教授。Farid博士目前担任Schr dinger和Ajax Therapeutics，Inc.的董事会成员。Ajax Therapeutics，Inc.是一家私营生物技术公司，应用计算化学和基于结构的技术开发用于血液系统恶性肿瘤的小分子。Farid博士以前是宾夕法尼亚大学生物化学和生物物理系的国家卫生研究所博士后研究员。Farid博士在罗切斯特大学获得化学学士学位，在加州理工学院获得化学博士学位。
- Ramy Farid,has served as a member of Structure Therapeutics Inc. board of directors since April 2019. Since January 2017, Dr. Farid has served as the President and Chief Executive Officer at Schrodinger, Inc. (Nasdaq: SDGR), where he has served in various roles since 1987, including President from January 2008 to December 2016, Senior Vice President from January 2005 to December 2007, and Vice President, Scientific Development and Product Management from January 2003 to December 2004. Prior to joining Schrodinger, Dr. Farid was an Assistant Professor in the Chemistry Department at Rutgers University from July 1994 to December 2001. Dr. Farid currently serves as a member of the board of directors of Schrdinger and Ajax Therapeutics, Inc. a private biotechnology company applying computational chemistry and structure-based technologies to develop small molecules for hematologic malignancies. Dr. Farid was previously a National Institute of Health Postdoctoral Fellow in the Department of Biochemistry and Biophysics at the University of Pennsylvania. Dr. Farid received his B.S. in Chemistry from the University of Rochester and his Ph.D. in Chemistry from the California Institute of Technology.
- Sharon Tetlow
-
Sharon Tetlow，自2022年3月起担任Structure Therapeutics公司董事会成员。自2016年1月以来，Tetlow女士担任Potrero Hill Advisors的管理合伙人，该公司是一家向生命科学公司提供战略和运营财务支持的咨询公司。在加入Potrero Hill Advisors之前，Tetlow女士在过去2年里担任过几家公共和私营生物技术公司的首席财务官。Tetlow女士目前在生物制药公司DICE Therapeutics, Inc.（Nasdaq：DICE）的董事会、提名和治理委员会以及审计委员会主席、生物制药公司Catalyst Biosciences, Inc.（Nasdaq：CBIO）的董事会以及审计委员会主席、Valneva SE（Nasdaq：VALN，EPA：VLA）的监事会以及审计委员会主席，Valneva SE是一家全球商业上市疫苗公司。Tetlow女士在特拉华大学获得心理学学士学位，在斯坦福大学获得工商管理硕士学位。
Sharon Tetlow,has served as a member of Structure Therapeutics Inc. board of directors since March 2022. Since January 2016, Ms. Tetlow has served as Managing Partner of Potrero Hill Advisors, an advisory firm providing strategic and operational financial support to life sciences companies. Prior to Potrero Hill Advisors, Ms. Tetlow served as chief financial officer of several public and private biotech companies for the previous twenty years. Ms. Tetlow currently serves on the board of directors, on the nominating and governance committee and as chair of the audit committee of DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company, on the board of directors and as chair of the audit committee of Catalyst Biosciences, Inc. (Nasdaq: CBIO), a biopharmaceutical company, and on the supervisory board and as chair of the audit committee of Valneva SE (Nasdaq: VALN, EPA: VLA), a global commercial stage, public vaccine company. Ms. Tetlow received her B.S. in Psychology from the University of Delaware and her M.B.A. from Stanford University. - Sharon Tetlow，自2022年3月起担任Structure Therapeutics公司董事会成员。自2016年1月以来，Tetlow女士担任Potrero Hill Advisors的管理合伙人，该公司是一家向生命科学公司提供战略和运营财务支持的咨询公司。在加入Potrero Hill Advisors之前，Tetlow女士在过去2年里担任过几家公共和私营生物技术公司的首席财务官。Tetlow女士目前在生物制药公司DICE Therapeutics, Inc.（Nasdaq：DICE）的董事会、提名和治理委员会以及审计委员会主席、生物制药公司Catalyst Biosciences, Inc.（Nasdaq：CBIO）的董事会以及审计委员会主席、Valneva SE（Nasdaq：VALN，EPA：VLA）的监事会以及审计委员会主席，Valneva SE是一家全球商业上市疫苗公司。Tetlow女士在特拉华大学获得心理学学士学位，在斯坦福大学获得工商管理硕士学位。
- Sharon Tetlow,has served as a member of Structure Therapeutics Inc. board of directors since March 2022. Since January 2016, Ms. Tetlow has served as Managing Partner of Potrero Hill Advisors, an advisory firm providing strategic and operational financial support to life sciences companies. Prior to Potrero Hill Advisors, Ms. Tetlow served as chief financial officer of several public and private biotech companies for the previous twenty years. Ms. Tetlow currently serves on the board of directors, on the nominating and governance committee and as chair of the audit committee of DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company, on the board of directors and as chair of the audit committee of Catalyst Biosciences, Inc. (Nasdaq: CBIO), a biopharmaceutical company, and on the supervisory board and as chair of the audit committee of Valneva SE (Nasdaq: VALN, EPA: VLA), a global commercial stage, public vaccine company. Ms. Tetlow received her B.S. in Psychology from the University of Delaware and her M.B.A. from Stanford University.
- Eric Dobmeier
-
Eric Dobmeier，自2022年12月起担任Structure Therapeutics公司董事会成员。Dobmeier先生自2019年4月起担任Chinook Therapeutics, Inc.（纳斯达克股票代码：KDNY）的总裁、首席执行官兼董事会成员，该公司是一家上市的生物技术公司，专注于肾脏疾病。在加入Chinook Therapeutics之前，Dobmeier先生于2018年1月至2018年6月担任Silverback Therapeutics，Inc.总裁兼首席执行官。在此之前，Dobmeier先生于2002年至2017年12月在生物技术上市公司Seattle Genetics, Inc.（纳斯达克股票代码：SGEN）担任越来越重要的职务，包括于2011年6月至2017年12月担任首席运营官。此前，Dobmeier先生是Venture Law Group和Heller Ehrman LLP律师事务所的一名律师，在那里他代表技术公司处理公共和私人融资、兼并和收购以及公司合伙交易。Dobmeier先生目前在Atara Biotherapeutics, Inc.（纳斯达克股票代码：ATRA）的董事会任职，该公司是一家上市的生物技术公司，自2015年起任职。Dobmeier先生此前曾于2016年至2021年在Adaptive Biotechnologies Corp（纳斯达克股票代码：ADPT）、2012年至2018年在Stemline Therapeutics, Inc.（纳斯达克股票代码：STML）以及2017年至2018年在Versartis的董事会任职，这两家公司都是一家上市的生物制药公司。他在普林斯顿大学获得历史学学士学位，在加州大学伯克利分校法学院获得法学博士学位。
Eric Dobmeier,has served as a member of Structure Therapeutics Inc. board of directors since December 2022. Since April 2019, Mr. Dobmeier has served as President, Chief Executive Officer and a member of the Board of Directors of Chinook Therapeutics, Inc. (NASDAQ: KDNY), a publicly traded biotechnology company focused on kidney diseases. Prior to joining Chinook Therapeutics, Mr. Dobmeier served as President and Chief Executive Officer of Silverback Therapeutics, Inc. from January 2018 to June 2018. Prior to that, Mr. Dobmeier held positions of increasing responsibility at Seattle Genetics, Inc. (NASDAQ: SGEN), a publicly traded biotechnology company, from 2002 to December 2017, including as Chief Operating Officer from June 2011 to December 2017. Previously, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP, where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier currently serves on the board of directors of Atara Biotherapeutics, Inc. (NASDAQ: ATRA), a publicly traded biotechnology company, where he has served since 2015. Mr. Dobmeier previously served on the boards of directors of Adaptive Biotechnologies Corp (NASDAQ: ADPT) from 2016 to 2021, Stemline Therapeutics, Inc. (NASDAQ: STML) from 2012 to 2018 and Versartis from 2017 to 2018, each a publicly traded biopharmaceutical company. He received his A.B. in History from Princeton University and his J.D. from the University of California, Berkeley School of Law. - Eric Dobmeier，自2022年12月起担任Structure Therapeutics公司董事会成员。Dobmeier先生自2019年4月起担任Chinook Therapeutics, Inc.（纳斯达克股票代码：KDNY）的总裁、首席执行官兼董事会成员，该公司是一家上市的生物技术公司，专注于肾脏疾病。在加入Chinook Therapeutics之前，Dobmeier先生于2018年1月至2018年6月担任Silverback Therapeutics，Inc.总裁兼首席执行官。在此之前，Dobmeier先生于2002年至2017年12月在生物技术上市公司Seattle Genetics, Inc.（纳斯达克股票代码：SGEN）担任越来越重要的职务，包括于2011年6月至2017年12月担任首席运营官。此前，Dobmeier先生是Venture Law Group和Heller Ehrman LLP律师事务所的一名律师，在那里他代表技术公司处理公共和私人融资、兼并和收购以及公司合伙交易。Dobmeier先生目前在Atara Biotherapeutics, Inc.（纳斯达克股票代码：ATRA）的董事会任职，该公司是一家上市的生物技术公司，自2015年起任职。Dobmeier先生此前曾于2016年至2021年在Adaptive Biotechnologies Corp（纳斯达克股票代码：ADPT）、2012年至2018年在Stemline Therapeutics, Inc.（纳斯达克股票代码：STML）以及2017年至2018年在Versartis的董事会任职，这两家公司都是一家上市的生物制药公司。他在普林斯顿大学获得历史学学士学位，在加州大学伯克利分校法学院获得法学博士学位。
- Eric Dobmeier,has served as a member of Structure Therapeutics Inc. board of directors since December 2022. Since April 2019, Mr. Dobmeier has served as President, Chief Executive Officer and a member of the Board of Directors of Chinook Therapeutics, Inc. (NASDAQ: KDNY), a publicly traded biotechnology company focused on kidney diseases. Prior to joining Chinook Therapeutics, Mr. Dobmeier served as President and Chief Executive Officer of Silverback Therapeutics, Inc. from January 2018 to June 2018. Prior to that, Mr. Dobmeier held positions of increasing responsibility at Seattle Genetics, Inc. (NASDAQ: SGEN), a publicly traded biotechnology company, from 2002 to December 2017, including as Chief Operating Officer from June 2011 to December 2017. Previously, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP, where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier currently serves on the board of directors of Atara Biotherapeutics, Inc. (NASDAQ: ATRA), a publicly traded biotechnology company, where he has served since 2015. Mr. Dobmeier previously served on the boards of directors of Adaptive Biotechnologies Corp (NASDAQ: ADPT) from 2016 to 2021, Stemline Therapeutics, Inc. (NASDAQ: STML) from 2012 to 2018 and Versartis from 2017 to 2018, each a publicly traded biopharmaceutical company. He received his A.B. in History from Princeton University and his J.D. from the University of California, Berkeley School of Law.
- Joanne Waldstreicher
-
Joanne Waldstreicher，她一直担任Structure Therapeutics公司的董事会成员（2022年12月以来）。自2012年12月起，Waldstreicher博士担任强生公司（NYSE： JNJ）的首席医疗官，自2002年起担任各种职务，包括强生Janssen Pharmaceutical Companies of Johnson & Johnson的亚太医学科学首席医疗官和主管（2011年至2012年），以及全球药物开发高级副总裁、主管（2007年至2009年）。在加入强生公司之前，Waldstreicher博士在默克研究实验室（Merck research Laboratories）负责内分泌学和代谢临床研究。Waldsteicher博士目前还担任纽约大学医学院（New York University School of Medicine）人口卫生系医学伦理部的附属教员。Waldstreicher博士在纽约城市大学布鲁克林学院获得化学学士学位，并在哈佛医学院获得医学博士学位。
Joanne Waldstreicher,has served as a member of Structure Therapeutics Inc. board of directors since December 2022. Since December 2012, Dr. Waldstreicher has served as Chief Medical Officer at Johnson & Johnson (NYSE: JNJ), where she has served in various roles since 2002, including Chief Medical Officer & Head, Asia Pacific Medical Science at Janssen Pharmaceutical Companies of Johnson & Johnson from 2011 to 2012 and Senior Vice President, Head, Global Drug Development from 2007 to 2009. Prior to joining Johnson & Johnson, Dr. Waldstreicher oversaw endocrinology and metabolism clinical research at Merck Research Laboratories. Dr. Waldstreicher also currently serves as a faculty affiliate of the Division of Medical Ethics, Department of Population Health at New York University School of Medicine. Dr. Waldstreicher received her B.A. in Chemistry at City University of New York, Brooklyn College, and her M.D. at Harvard Medical School. - Joanne Waldstreicher，她一直担任Structure Therapeutics公司的董事会成员（2022年12月以来）。自2012年12月起，Waldstreicher博士担任强生公司（NYSE： JNJ）的首席医疗官，自2002年起担任各种职务，包括强生Janssen Pharmaceutical Companies of Johnson & Johnson的亚太医学科学首席医疗官和主管（2011年至2012年），以及全球药物开发高级副总裁、主管（2007年至2009年）。在加入强生公司之前，Waldstreicher博士在默克研究实验室（Merck research Laboratories）负责内分泌学和代谢临床研究。Waldsteicher博士目前还担任纽约大学医学院（New York University School of Medicine）人口卫生系医学伦理部的附属教员。Waldstreicher博士在纽约城市大学布鲁克林学院获得化学学士学位，并在哈佛医学院获得医学博士学位。
- Joanne Waldstreicher,has served as a member of Structure Therapeutics Inc. board of directors since December 2022. Since December 2012, Dr. Waldstreicher has served as Chief Medical Officer at Johnson & Johnson (NYSE: JNJ), where she has served in various roles since 2002, including Chief Medical Officer & Head, Asia Pacific Medical Science at Janssen Pharmaceutical Companies of Johnson & Johnson from 2011 to 2012 and Senior Vice President, Head, Global Drug Development from 2007 to 2009. Prior to joining Johnson & Johnson, Dr. Waldstreicher oversaw endocrinology and metabolism clinical research at Merck Research Laboratories. Dr. Waldstreicher also currently serves as a faculty affiliate of the Division of Medical Ethics, Department of Population Health at New York University School of Medicine. Dr. Waldstreicher received her B.A. in Chemistry at City University of New York, Brooklyn College, and her M.D. at Harvard Medical School.
- Daniel G. Welch
-
Daniel G. Welch，2007年6月起任公司董事。2003年9月起，他是生物科技公司 InterMune, Inc.的首席执行官和总裁。2007年5月，他还担任InterMune的董事会主席。加入InterMune前，2002至2003年他是Triangle Pharmaceuticals 的主席和首席执行官，该公司2003年被Gilead收购。此前的2000至2002年，他是Elan Corporation生物制药部总裁。在Elan任职期间，他负责美国市场商业运营、国际子公司、研发和诊断业务。1987至2000年，他担任Sanofi-Synthelabo（现Sanofi-Aventis）多个高级管理职位，包括国际市场部副总裁、美国业务部首席运营官等。他获有University of Miami学士学位，以及University of North Carolina的工商管理硕士学位。除Seattle Genetics外，他还担任上市生物科技公司InterMune, Hyperion Therapeutics, Inc.和民营生物科技公司Corium International, Inc.的董事。
Daniel G. Welch,Sofinnova Ventures, a venture capital firm,Executive Partner 2015-2018; retired.InterMune, Inc., a publicly-traded biotechnology company,Chief Executive Officer and President (2003-2014),Chairman of the Board (2007-2014).Intercept Pharmaceuticals, Inc.,Ultragenyx Pharmaceuticals, Inc. (Chairman of the Board),Hyperion Therapeutics, Avexis, Inc.. - Daniel G. Welch，2007年6月起任公司董事。2003年9月起，他是生物科技公司 InterMune, Inc.的首席执行官和总裁。2007年5月，他还担任InterMune的董事会主席。加入InterMune前，2002至2003年他是Triangle Pharmaceuticals 的主席和首席执行官，该公司2003年被Gilead收购。此前的2000至2002年，他是Elan Corporation生物制药部总裁。在Elan任职期间，他负责美国市场商业运营、国际子公司、研发和诊断业务。1987至2000年，他担任Sanofi-Synthelabo（现Sanofi-Aventis）多个高级管理职位，包括国际市场部副总裁、美国业务部首席运营官等。他获有University of Miami学士学位，以及University of North Carolina的工商管理硕士学位。除Seattle Genetics外，他还担任上市生物科技公司InterMune, Hyperion Therapeutics, Inc.和民营生物科技公司Corium International, Inc.的董事。
- Daniel G. Welch,Sofinnova Ventures, a venture capital firm,Executive Partner 2015-2018; retired.InterMune, Inc., a publicly-traded biotechnology company,Chief Executive Officer and President (2003-2014),Chairman of the Board (2007-2014).Intercept Pharmaceuticals, Inc.,Ultragenyx Pharmaceuticals, Inc. (Chairman of the Board),Hyperion Therapeutics, Avexis, Inc..
高管简历
中英对照 | 中文 | 英文- Raymond Stevens
Raymond Stevens自2019年5月起担任Structure Therapeutics公司首席执行官，自2019年2月起担任Structure Therapeutics公司董事会成员。此前，Stevens博士在南加州大学创立了Bridge研究所，即Bridge研究所，2014年7月至2019年5月担任创始主任和教授，此后担任名誉教授。在创立Bridge Institute之前，Stevens博士于2012年1月在上海科技大学创立了iHuman Institute，即iHuman Institute，此后他一直担任创始董事和兼职教授。在创立iHuman研究所之前，Stevens博士于1999年6月至2014年7月担任斯克里普斯研究所综合结构和计算生物学和化学系教授。史蒂文斯博士目前还担任丹纳赫公司（纽约证券交易所代码：DHR）的董事会成员。史蒂文斯博士在哈佛大学完成了化学博士后研究。Stevens博士在南缅因大学获得化学学士学位，在南加州大学获得有机化学博士学位。
Raymond Stevens,has served as Structure Therapeutics Inc. Chief Executive Officer since May 2019 and as a member of Structure Therapeutics Inc. board of directors since February 2019. Previously, Dr. Stevens founded the Bridge Institute at the University of Southern California, or Bridge Institute, where he served as Founding Director and Professor from July 2014 to May 2019, and since then as Professor Emeritus. Prior to founding the Bridge Institute, Dr. Stevens founded the iHuman Institute at ShanghaiTech University, or iHuman Institute, in January 2012, where he has since served as Founding Director and Adjunct Professor. Prior to founding the iHuman Institute, Dr. Stevens served as Professor, Department of Integrative Structural and Computational Biology and Chemistry at The Scripps Research Institute from June 1999 to July 2014. Dr. Stevens also currently serves as a member of the board of directors of Danaher Corporation (NYSE: DHR). Dr. Stevens completed a post-doctoral fellowship in Chemistry at Harvard University. Dr. Stevens received his B.A. in Chemistry from the University of Southern Maine, and his Ph.D. in Organic Chemistry from the University of Southern California.- Raymond Stevens自2019年5月起担任Structure Therapeutics公司首席执行官，自2019年2月起担任Structure Therapeutics公司董事会成员。此前，Stevens博士在南加州大学创立了Bridge研究所，即Bridge研究所，2014年7月至2019年5月担任创始主任和教授，此后担任名誉教授。在创立Bridge Institute之前，Stevens博士于2012年1月在上海科技大学创立了iHuman Institute，即iHuman Institute，此后他一直担任创始董事和兼职教授。在创立iHuman研究所之前，Stevens博士于1999年6月至2014年7月担任斯克里普斯研究所综合结构和计算生物学和化学系教授。史蒂文斯博士目前还担任丹纳赫公司（纽约证券交易所代码：DHR）的董事会成员。史蒂文斯博士在哈佛大学完成了化学博士后研究。Stevens博士在南缅因大学获得化学学士学位，在南加州大学获得有机化学博士学位。
- Raymond Stevens,has served as Structure Therapeutics Inc. Chief Executive Officer since May 2019 and as a member of Structure Therapeutics Inc. board of directors since February 2019. Previously, Dr. Stevens founded the Bridge Institute at the University of Southern California, or Bridge Institute, where he served as Founding Director and Professor from July 2014 to May 2019, and since then as Professor Emeritus. Prior to founding the Bridge Institute, Dr. Stevens founded the iHuman Institute at ShanghaiTech University, or iHuman Institute, in January 2012, where he has since served as Founding Director and Adjunct Professor. Prior to founding the iHuman Institute, Dr. Stevens served as Professor, Department of Integrative Structural and Computational Biology and Chemistry at The Scripps Research Institute from June 1999 to July 2014. Dr. Stevens also currently serves as a member of the board of directors of Danaher Corporation (NYSE: DHR). Dr. Stevens completed a post-doctoral fellowship in Chemistry at Harvard University. Dr. Stevens received his B.A. in Chemistry from the University of Southern Maine, and his Ph.D. in Organic Chemistry from the University of Southern California.
- Jun Yoon
Jun Yoon自2022年5月起担任Structure Therapeutics公司首席财务官。他曾于2019年2月起担任Structure Therapeutics Inc.首席运营官。在加入Structure Therapeutics公司之前，Yoon先生曾于2010年5月至2016年1月在Cellerant Therapeutics公司担任公司发展副总裁，该公司是一家生物技术公司，致力于开发针对血液系统恶性肿瘤和其他血液相关疾病的免疫疗法。在加入Cellerant Therapeutics公司之前，Yoon先生曾于2004年8月至2010年3月在专注于心血管疾病治疗的生物技术公司VIA Pharmaceuticals，Inc.担任许可和业务发展高级总监。Yoon先生在此之前于2000年7月至2002年10月在Syrrx，Inc.的业务发展部门工作，在该公司被Takeda Pharmaceutical Company Limited收购之前。Yoon先生目前担任GPCR联盟的主任，该联盟是一个推动GPCR研究的全球公私合作组织。Yoon先生在加州大学伯克利分校获得分子细胞生物学学士学位。
Jun Yoon,has served as Structure Therapeutics Inc. Chief Financial Officer since May 2022. He previously served as Structure Therapeutics Inc. Chief Operating Officer since February 2019. Prior to joining Structure Therapeutics Inc. company, Mr. Yoon served as Vice President, Corporate Development at Cellerant Therapeutics, Inc., a biotechnology company developing immunotherapies for hematologic malignancies and other blood-related disorders, from May 2010 to January 2016. Prior to joining Cellerant Therapeutics, Mr. Yoon served as Senior Director, Licensing & Business Development at VIA Pharmaceuticals, Inc., a biotechnology company focused on the treatment of cardiovascular disease, from August 2004 to March 2010. Previously, Mr. Yoon worked in Business Development for Syrrx, Inc., prior to its acquisition by Takeda Pharmaceutical Company Limited, from July 2000 to October 2002. Mr. Yoon currently serves as director of the GPCR Consortium, a public-private global collaboration advancing GPCR research. Mr. Yoon received his B.A. in Molecular Cell Biology from the University of California, Berkeley.- Jun Yoon自2022年5月起担任Structure Therapeutics公司首席财务官。他曾于2019年2月起担任Structure Therapeutics Inc.首席运营官。在加入Structure Therapeutics公司之前，Yoon先生曾于2010年5月至2016年1月在Cellerant Therapeutics公司担任公司发展副总裁，该公司是一家生物技术公司，致力于开发针对血液系统恶性肿瘤和其他血液相关疾病的免疫疗法。在加入Cellerant Therapeutics公司之前，Yoon先生曾于2004年8月至2010年3月在专注于心血管疾病治疗的生物技术公司VIA Pharmaceuticals，Inc.担任许可和业务发展高级总监。Yoon先生在此之前于2000年7月至2002年10月在Syrrx，Inc.的业务发展部门工作，在该公司被Takeda Pharmaceutical Company Limited收购之前。Yoon先生目前担任GPCR联盟的主任，该联盟是一个推动GPCR研究的全球公私合作组织。Yoon先生在加州大学伯克利分校获得分子细胞生物学学士学位。
- Jun Yoon,has served as Structure Therapeutics Inc. Chief Financial Officer since May 2022. He previously served as Structure Therapeutics Inc. Chief Operating Officer since February 2019. Prior to joining Structure Therapeutics Inc. company, Mr. Yoon served as Vice President, Corporate Development at Cellerant Therapeutics, Inc., a biotechnology company developing immunotherapies for hematologic malignancies and other blood-related disorders, from May 2010 to January 2016. Prior to joining Cellerant Therapeutics, Mr. Yoon served as Senior Director, Licensing & Business Development at VIA Pharmaceuticals, Inc., a biotechnology company focused on the treatment of cardiovascular disease, from August 2004 to March 2010. Previously, Mr. Yoon worked in Business Development for Syrrx, Inc., prior to its acquisition by Takeda Pharmaceutical Company Limited, from July 2000 to October 2002. Mr. Yoon currently serves as director of the GPCR Consortium, a public-private global collaboration advancing GPCR research. Mr. Yoon received his B.A. in Molecular Cell Biology from the University of California, Berkeley.
- Xichen Lin
林喜辰自2019年7月起担任Structure Therapeutics公司首席科学官。在加入Structure Therapeutics Inc.公司之前，林博士于2016年5月至2019年7月在诺和诺德担任亚太区外部创新主管。在加入Novo Nordisk A/S之前，林博士于2015年12月至2016年5月在生物技术投资公司C-Bridge Capital担任运营合伙人。在任职于C-Bridge Capital之前，林博士曾于2002年7月至2015年12月在葛兰素史克（GlaxoSmithKline）或GSK担任多个科学和战略职务，包括GSK全球神经炎症发现业绩部门的负责人。林博士在北京大学获得化学学士学位，在宾夕法尼亚州立大学获得有机化学博士学位。
Xichen Lin,has served as Structure Therapeutics Inc. Chief Scientific Officer since July 2019. Prior to joining Structure Therapeutics Inc. company, Dr. Lin served as Head of External Innovation, Asia Pacific at Novo Nordisk from May 2016 to July 2019. Prior to joining Novo Nordisk A/S, Dr. Lin served as Operation Partner at C-Bridge Capital, a biotechnology investment firm, from December 2015 to May 2016. Prior to serving at C-Bridge Capital, Dr. Lin held various scientific and strategy roles at GlaxoSmithKline, or GSK, from July 2002 to December 2015, including Head of GSK's Global Neuroinflammation Discovery Performance Unit. Dr. Lin received his B.S. in Chemistry from Peking University, and his Ph.D. in Organic Chemistry from The Pennsylvania State University.- 林喜辰自2019年7月起担任Structure Therapeutics公司首席科学官。在加入Structure Therapeutics Inc.公司之前，林博士于2016年5月至2019年7月在诺和诺德担任亚太区外部创新主管。在加入Novo Nordisk A/S之前，林博士于2015年12月至2016年5月在生物技术投资公司C-Bridge Capital担任运营合伙人。在任职于C-Bridge Capital之前，林博士曾于2002年7月至2015年12月在葛兰素史克（GlaxoSmithKline）或GSK担任多个科学和战略职务，包括GSK全球神经炎症发现业绩部门的负责人。林博士在北京大学获得化学学士学位，在宾夕法尼亚州立大学获得有机化学博士学位。
- Xichen Lin,has served as Structure Therapeutics Inc. Chief Scientific Officer since July 2019. Prior to joining Structure Therapeutics Inc. company, Dr. Lin served as Head of External Innovation, Asia Pacific at Novo Nordisk from May 2016 to July 2019. Prior to joining Novo Nordisk A/S, Dr. Lin served as Operation Partner at C-Bridge Capital, a biotechnology investment firm, from December 2015 to May 2016. Prior to serving at C-Bridge Capital, Dr. Lin held various scientific and strategy roles at GlaxoSmithKline, or GSK, from July 2002 to December 2015, including Head of GSK's Global Neuroinflammation Discovery Performance Unit. Dr. Lin received his B.S. in Chemistry from Peking University, and his Ph.D. in Organic Chemistry from The Pennsylvania State University.
- Mark Bach
Mark Bach，自2021年6月起担任Structure Therapeutics公司首席医疗官。在加入Structure Therapeutics公司之前，Bach博士于2020年11月至2021年6月在丹麦生物制药公司Ascendis Pharma担任内分泌医学高级副总裁。在任职于Ascendis制药公司（纳斯达克股票代码：ASND）之前，Bach博士于2020年7月至2020年10月担任非营利性生物制药信息交流平台Accumulus Synergy，Inc.的临时首席执行官。在加入Accumulus Synergy之前，Bach博士曾于2010年1月至2020年10月在杨森制药公司（Janssen Pharmaceuticals，Inc.）担任多个职务，包括副总裁、首席医疗官办公室以及亚太医学科学和中国创新副总裁。在加入杨森之前，巴赫博士于1993年6月至2010年1月在默克公司（纽约证券交易所代码：MRK）担任过多个职务，包括全球医疗组织副总裁兼执行董事。巴赫博士在卡尔顿学院获得化学学士学位，在芝加哥大学生物科学研究生院获得病理学博士学位，在贝勒医学院获得医学博士学位。
Mark Bach,has served as Structure Therapeutics Inc. Chief Medical Officer since June 2021. Prior to joining Structure Therapeutics Inc. company, Dr. Bach served as Senior Vice President, Endocrine Medical Sciences at Ascendis Pharma, a Danish biopharmaceutical company, from November 2020 to June 2021. Prior to serving at Ascendis Pharma, Inc. (Nasdaq: ASND), Dr. Bach served as Interim Chief Executive Officer of Accumulus Synergy, Inc., a non-profit biopharmaceutical information exchange platform, from July 2020 to October 2020. Prior to serving at Accumulus Synergy, Dr. Bach held various roles at Janssen Pharmaceuticals, Inc., or Janssen, from January 2010 to October 2020, including Vice President, Office of the Chief Medical Officer and Vice President Head, Asia Pacific Medical Sciences and China Innovation. Prior to serving at Janssen, Dr. Bach held various roles at Merck & Co., Inc. (NYSE: MRK) from June 1993 to January 2010, including Vice President and Executive Director, Global Medical Organization. Dr. Bach received his B.A. in Chemistry from Carleton College, his Ph.D. in Pathology from The University of Chicago Graduate School of Biological Sciences, and his M.D. from Baylor College of Medicine.- Mark Bach，自2021年6月起担任Structure Therapeutics公司首席医疗官。在加入Structure Therapeutics公司之前，Bach博士于2020年11月至2021年6月在丹麦生物制药公司Ascendis Pharma担任内分泌医学高级副总裁。在任职于Ascendis制药公司（纳斯达克股票代码：ASND）之前，Bach博士于2020年7月至2020年10月担任非营利性生物制药信息交流平台Accumulus Synergy，Inc.的临时首席执行官。在加入Accumulus Synergy之前，Bach博士曾于2010年1月至2020年10月在杨森制药公司（Janssen Pharmaceuticals，Inc.）担任多个职务，包括副总裁、首席医疗官办公室以及亚太医学科学和中国创新副总裁。在加入杨森之前，巴赫博士于1993年6月至2010年1月在默克公司（纽约证券交易所代码：MRK）担任过多个职务，包括全球医疗组织副总裁兼执行董事。巴赫博士在卡尔顿学院获得化学学士学位，在芝加哥大学生物科学研究生院获得病理学博士学位，在贝勒医学院获得医学博士学位。
- Mark Bach,has served as Structure Therapeutics Inc. Chief Medical Officer since June 2021. Prior to joining Structure Therapeutics Inc. company, Dr. Bach served as Senior Vice President, Endocrine Medical Sciences at Ascendis Pharma, a Danish biopharmaceutical company, from November 2020 to June 2021. Prior to serving at Ascendis Pharma, Inc. (Nasdaq: ASND), Dr. Bach served as Interim Chief Executive Officer of Accumulus Synergy, Inc., a non-profit biopharmaceutical information exchange platform, from July 2020 to October 2020. Prior to serving at Accumulus Synergy, Dr. Bach held various roles at Janssen Pharmaceuticals, Inc., or Janssen, from January 2010 to October 2020, including Vice President, Office of the Chief Medical Officer and Vice President Head, Asia Pacific Medical Sciences and China Innovation. Prior to serving at Janssen, Dr. Bach held various roles at Merck & Co., Inc. (NYSE: MRK) from June 1993 to January 2010, including Vice President and Executive Director, Global Medical Organization. Dr. Bach received his B.A. in Chemistry from Carleton College, his Ph.D. in Pathology from The University of Chicago Graduate School of Biological Sciences, and his M.D. from Baylor College of Medicine.
- Melita Sun Jung
Melita Sun Jung，自2021年5月起担任Structure Therapeutics Inc.首席商务官。在加入Structure Therapeutics公司之前，Jung女士于2017年7月至2021年5月在基因组药物公司Sangamo Therapeutics, Inc.（Nasdaq：SGMO）担任高级副总裁兼业务发展主管。在加入Sangamo Therapeutics之前，Jung女士于2014年7月至2017年6月在Adamas Pharmaceuticals, Inc.（一家专注于神经系统疾病的生物制药公司）担任企业发展高级总监。在此之前，Jung女士于2012年4月至2014年5月在Ascendancy Healthcare，Inc.担任业务发展副总裁，该公司专注于为中国和其他亚洲市场商业化医药产品。在Ascendancy Healthcare任职之前，Jung女士曾在Ipsen，Ltd.（OTCMKTS：IPSEY）担任企业开发和商业职务，Ipsen，Ltd.是一家专注于肿瘤学、罕见病和神经科学的生物制药公司。此前，荣格在Bay City Capital和Lombard Odier开始了她的风险投资和基金管理生涯。Jung女士在加州大学伯克利分校获得了综合生物学学士学位。
Melita Sun Jung,has served as Structure Therapeutics Inc. Chief Business Officer since May 2021. Prior to joining Structure Therapeutics Inc. company, Ms. Jung served as Senior Vice President, Head of Business Development at Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, from July 2017 to May 2021. Prior to joining Sangamo Therapeutics, Ms. Jung served as Senior Director, Corporate Development at Adamas Pharmaceuticals, Inc., a biopharmaceutical company focused on neurological diseases, from July 2014 to June 2017. Prior to that, Ms. Jung served as Vice President, Business Development at Ascendancy Healthcare, Inc., a company focused on commercializing pharmaceutical products for China and other Asian markets, from April 2012 to May 2014. Prior to serving at Ascendancy Healthcare, Ms. Jung held corporate development and commercial roles for Ipsen, Ltd. (OTCMKTS: IPSEY), a biopharmaceutical company focused on oncology, rare disease and neuroscience. Previously, Ms. Jung started her career in venture capital and fund management, at Bay City Capital and Lombard Odier. Ms. Jung received her B.A. in Integrative Biology from the University of California, Berkeley.- Melita Sun Jung，自2021年5月起担任Structure Therapeutics Inc.首席商务官。在加入Structure Therapeutics公司之前，Jung女士于2017年7月至2021年5月在基因组药物公司Sangamo Therapeutics, Inc.（Nasdaq：SGMO）担任高级副总裁兼业务发展主管。在加入Sangamo Therapeutics之前，Jung女士于2014年7月至2017年6月在Adamas Pharmaceuticals, Inc.（一家专注于神经系统疾病的生物制药公司）担任企业发展高级总监。在此之前，Jung女士于2012年4月至2014年5月在Ascendancy Healthcare，Inc.担任业务发展副总裁，该公司专注于为中国和其他亚洲市场商业化医药产品。在Ascendancy Healthcare任职之前，Jung女士曾在Ipsen，Ltd.（OTCMKTS：IPSEY）担任企业开发和商业职务，Ipsen，Ltd.是一家专注于肿瘤学、罕见病和神经科学的生物制药公司。此前，荣格在Bay City Capital和Lombard Odier开始了她的风险投资和基金管理生涯。Jung女士在加州大学伯克利分校获得了综合生物学学士学位。
- Melita Sun Jung,has served as Structure Therapeutics Inc. Chief Business Officer since May 2021. Prior to joining Structure Therapeutics Inc. company, Ms. Jung served as Senior Vice President, Head of Business Development at Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, from July 2017 to May 2021. Prior to joining Sangamo Therapeutics, Ms. Jung served as Senior Director, Corporate Development at Adamas Pharmaceuticals, Inc., a biopharmaceutical company focused on neurological diseases, from July 2014 to June 2017. Prior to that, Ms. Jung served as Vice President, Business Development at Ascendancy Healthcare, Inc., a company focused on commercializing pharmaceutical products for China and other Asian markets, from April 2012 to May 2014. Prior to serving at Ascendancy Healthcare, Ms. Jung held corporate development and commercial roles for Ipsen, Ltd. (OTCMKTS: IPSEY), a biopharmaceutical company focused on oncology, rare disease and neuroscience. Previously, Ms. Jung started her career in venture capital and fund management, at Bay City Capital and Lombard Odier. Ms. Jung received her B.A. in Integrative Biology from the University of California, Berkeley.
- Yingli Ma
马英利自2022年8月起担任Structure Therapeutics公司首席技术官。此前，马博士于2021年5月至2022年8月担任Basecamp Bio Inc.总经理兼总裁，该公司为Structure Therapeutics Inc.的全资子公司。在加入Basecamp生物之前，马博士曾于2020年6月至2021年5月担任安进生物制药研发（上海）总经理，该公司是安进公司（Nasdaq：AMGN）的研发基地。此前，马博士曾在安进公司担任多个职务，包括2018年7月至2019年12月担任结构生物学和中研上海平台执行董事，2014年6月至2018年7月担任结构生物学和蛋白质表达首席科学家。在任职于安进公司之前，马博士于2009年4月至2014年5月担任GSK高级科学家兼结构化学主管首席科学家。马博士在洛克菲勒大学完成了分子生物学的博士后研究。马博士在中国医科大学获得临床医学学士学位，在宾夕法尼亚大学获得生物化学和分子生物物理学博士学位。
Yingli Ma,has served as Structure Therapeutics Inc. Chief Technology Officer since August 2022. Previously, Dr. Ma served as General Manager and President of Basecamp Bio Inc., Structure Therapeutics Inc. wholly-owned subsidiary, from May 2021 to August 2022. Prior to joining Basecamp Bio, Dr. Ma served as General Manager of Amgen Biopharmaceutical R&D (Shanghai), the R&D site of Amgen, Inc. (Nasdaq: AMGN) in Shanghai from June 2020 to May 2021. Previously, Dr. Ma served in various roles at Amgen, including Executive Director, Structural Biology and China Research Shanghai, or CNRS, Platforms from July 2018 to December 2019, and Principal Scientist, Structural Biology and Protein Expression from June 2014 to July 2018. Prior to serving at Amgen, Dr. Ma was Senior Scientist and Principal Scientist, Structural Chemistry Lead at GSK from April 2009 to May 2014. Dr. Ma completed her post-doctoral fellowship in Molecular Biology at Rockefeller University. Dr. Ma received her B.S. in Clinical Medicine from China Medical University, and her Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania.- 马英利自2022年8月起担任Structure Therapeutics公司首席技术官。此前，马博士于2021年5月至2022年8月担任Basecamp Bio Inc.总经理兼总裁，该公司为Structure Therapeutics Inc.的全资子公司。在加入Basecamp生物之前，马博士曾于2020年6月至2021年5月担任安进生物制药研发（上海）总经理，该公司是安进公司（Nasdaq：AMGN）的研发基地。此前，马博士曾在安进公司担任多个职务，包括2018年7月至2019年12月担任结构生物学和中研上海平台执行董事，2014年6月至2018年7月担任结构生物学和蛋白质表达首席科学家。在任职于安进公司之前，马博士于2009年4月至2014年5月担任GSK高级科学家兼结构化学主管首席科学家。马博士在洛克菲勒大学完成了分子生物学的博士后研究。马博士在中国医科大学获得临床医学学士学位，在宾夕法尼亚大学获得生物化学和分子生物物理学博士学位。
- Yingli Ma,has served as Structure Therapeutics Inc. Chief Technology Officer since August 2022. Previously, Dr. Ma served as General Manager and President of Basecamp Bio Inc., Structure Therapeutics Inc. wholly-owned subsidiary, from May 2021 to August 2022. Prior to joining Basecamp Bio, Dr. Ma served as General Manager of Amgen Biopharmaceutical R&D (Shanghai), the R&D site of Amgen, Inc. (Nasdaq: AMGN) in Shanghai from June 2020 to May 2021. Previously, Dr. Ma served in various roles at Amgen, including Executive Director, Structural Biology and China Research Shanghai, or CNRS, Platforms from July 2018 to December 2019, and Principal Scientist, Structural Biology and Protein Expression from June 2014 to July 2018. Prior to serving at Amgen, Dr. Ma was Senior Scientist and Principal Scientist, Structural Chemistry Lead at GSK from April 2009 to May 2014. Dr. Ma completed her post-doctoral fellowship in Molecular Biology at Rockefeller University. Dr. Ma received her B.S. in Clinical Medicine from China Medical University, and her Ph.D. in Biochemistry and Molecular Biophysics from the University of Pennsylvania.